OTCMKTS:BIOYF BioSyent (BIOYF) Stock Price, News & Analysis $9.89 0.00 (0.00%) As of 05/22/2026 02:53 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesShort InterestBuy This Stock About BioSyent Stock (OTCMKTS:BIOYF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioSyent alerts:Sign Up Key Stats Today's Range$9.83▼$10.1150-Day Range$9.89▼$11.6052-Week Range$7.63▼$12.00Volume7,068 shsAverage Volume2,310 shsMarket CapitalizationN/AP/E Ratio48.60Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview BioSyent Inc. is a specialty biopharmaceutical company focused on developing, manufacturing and commercializing pharmaceutical products and medical devices. The company leverages expertise in regulatory affairs, clinical development and manufacturing to deliver a range of branded and generic therapies across multiple therapeutic areas, with particular emphasis on endocrine disorders, supportive care oncology and dermatology. BioSyent operates a manufacturing facility in Canada that supports both its proprietary portfolio and contract development and manufacturing services (CDMO) for small-molecule products. Its end-to-end capabilities—encompassing formulation, fill-finish and quality testing—serve clients in North America and selected international markets. The company's commercial footprint spans Canada and the United States, where it markets specialty pharmaceuticals through its dedicated sales force and distribution partnerships. BioSyent continues to bolster its product pipeline through strategic in-licensing, acquisitions and targeted internal development programs, aiming to address evolving patient needs in niche therapeutic segments. Guided by an experienced leadership team with backgrounds in pharmaceutical development and commercialization, BioSyent is focused on sustainable growth through portfolio expansion and manufacturing capacity enhancement. The company's strategy emphasizes high-value specialty products, positioning BioSyent to respond to emerging healthcare trends and regulatory opportunities.AI Generated. May Contain Errors. Read More Receive BIOYF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioSyent and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIOYF Stock News HeadlinesBioSyent Announces Health Canada Approval of Thyconvi™ (levothyroxine oral solution)May 19, 2026 | globenewswire.comBioSyent Declares Second Quarter 2026 DividendMay 14, 2026 | globenewswire.comThis stock has 30 days of quiet leftA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When the SpaceX and xAI S-1 filing hits the SEC in June, analysts will comb through supplier disclosures and this company's name is expected to surface. Dylan Jovine has identified the ticker and laid out the full investment thesis. The stock is still quiet - but that window may be closing fast.May 26 at 1:00 AM | Behind the Markets (Ad)BioSyent Releases Financial Results for First Quarter 2026May 14, 2026 | globenewswire.comBioSyent Schedules First Quarter 2026 Earnings Release for May 14, 2026May 7, 2026 | globenewswire.comBioSyent to Present at 2026 Bloom Burton & Co. Healthcare Investor ConferenceApril 15, 2026 | globenewswire.comBioSyent Announces Grant of Restricted Share UnitsMarch 24, 2026 | globenewswire.comBioSyent Releases Financial Results for Fourth Quarter and Full Year 2025March 19, 2026 | globenewswire.comSee More Headlines BIOYF Stock Analysis - Frequently Asked Questions How have BIOYF shares performed this year? BioSyent's stock was trading at $9.52 at the start of the year. Since then, BIOYF stock has increased by 3.9% and is now trading at $9.89. How do I buy shares of BioSyent? Shares of BIOYF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:BIOYF CIKN/A Webwww.biosyent.com Phone(905) 206-0013FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio48.60 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Don't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (OTCMKTS:BIOYF) was last updated on 5/26/2026 by MarketBeat.com Staff. From Our PartnersOpportunity Forming in a U.S. Supply-Chain Weak Spot?America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...i2i Marketing Group, LLC | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredThe S-1 just dropped. 22 days left.The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...Behind the Markets | SponsoredOne algorithm, 17 years, nearly 2,000% total returnsA physicist in Dublin claims his AI algorithm has beaten the market for 17 consecutive years - with nearly 2,0...Porter & Company | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioSyent Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioSyent With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.